Edition:
United States

Catalyst Pharmaceuticals Inc (CPRX.O)

CPRX.O on Consolidated Issue listed on NASDAQ Capital Market

1.09USD
30 Sep 2016
Change (% chg)

$-0.03 (-2.68%)
Prev Close
$1.12
Open
$1.14
Day's High
$1.14
Day's Low
$1.07
Volume
513,970
Avg. Vol
928,624
52-wk High
$3.55
52-wk Low
$0.51

CPRX.O

Chart for CPRX.O

About

Catalyst Pharmaceuticals, Inc., formerly Catalyst Pharmaceutical Partners, Inc., is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115. The Company's... (more)

Overall

Beta: 1.26
Market Cap(Mil.): $90.33
Shares Outstanding(Mil.): 82.87
Dividend: --
Yield (%): --

Financials

  CPRX.O Industry Sector
P/E (TTM): -- 43.83 36.83
EPS (TTM): -0.24 -- --
ROI: -35.97 -0.29 13.93
ROE: -37.06 -2.99 14.84

BRIEF-Catalyst Pharmaceuticals' board entered into amendment no. 1 to rights agreement

* On September 19, 2016, board unanimously approved, and entered into amendment no. 1 to rights agreement - SEC filing

Sep 20 2016

BRIEF-Catalyst Pharmaceuticals announces FDA orphan drug designation of Firdapse

* Catalyst Pharmaceuticals announces FDA orphan drug designation of Firdapse for the treatment of Myasthenia Gravis

Sep 02 2016

BRIEF-Catalyst Pharmaceuticals announce Q2 2016 financial results and provides product development update

* Catalyst Pharmaceuticals announces second quarter 2016 financial results and provides product development update

Aug 09 2016

BRIEF-Catalyst Pharma finalizes late-stage trial design with FDA for Firdapse

* Catalyst Pharmaceuticals announces agreement with FDA on confirmatory phase 3 study protocol for Firdapse in Lambert-Eaton Myasthenic Syndrome

Jun 13 2016

BRIEF-Catalyst Pharmaceuticals announces reduction in workforce

* Announces reduction in workforce as part of operating expense management plan

May 17 2016

BRIEF-Catalyst Pharmaceuticals posts Q1 GAAP loss of $0.07/shr

* Believe current resources give sufficient runway for at least next year

May 10 2016

BRIEF-Catalyst pharmaceuticals provides regulatory update on Firdapse

* Catalyst pharmaceuticals provides regulatory update on firdapse Source text for Eikon: Further company coverage:

Apr 26 2016

Earnings vs. Estimates